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BR provided a statistically signiﬁcant reduction in overall hospitalisations rates and 
costs versus placebo  BR. Reductions in hospitalisation time indicate signiﬁcant 
savings to the health care system and clinical beneﬁt to the patients.
INFECTION – Patient-Reported Outcomes Studies
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OBJECTIVES: Fixed-dose combination (FDC) products consisting of q2 antiretrovi-
rals in one tablet improve adherence compared to the same agents taken separately. 
The impact of FDC products on adherence to other regimen components has not been 
assessed. We used pharmacy records to evaluate whether an FDC product improves 
HIV patients’ adherence to a 3rd regimen agent. METHODS: Data from 1997–2005 
were taken from IHCIS Managed Care Benchmark Database, a national sample of 30 
health plans covering ^38M lives. We compared adherence to the 3rd regimen com-
ponent among patients with q1 pharmacy claim for the FDC Epzicom (abacavir sulfate 
600 mg  lamivudine 300 mg) versus 2 NRTIs as separate pills (SP). Adherence was 
measured as the medication possession ratio (MPR). Multivariate logistic regression 
compared treatment groups based on the likelihood of achieving q95% adherence, 
with sensitivity analyses across other adherence thresholds. Multivariate linear regres-
sion assessed the effect of treatment group on MPR as a continuous variable. Covari-
ates included age, gender, insurance payer type, year of study drug initiation, presence 
of mental health and substance abuse disorders, and 3rd agent class. RESULTS: The 
sample consisted of 650 FDC and 1947 SP patients. Unadjusted mean adherence to 
the 3rd agent was higher in the FDC than the SP group (0.92 vs 0.85; p  0.0001). 
Adjusting for covariates, FDC patients were 48% and 39% more likely to achieve 
95% and 90% adherence to the 3rd agent, respectively (p  0.05 for each). These 
results did not hold for other MPR speciﬁcations. CONCLUSIONS: For patients 
enrolled in managed care plans, use of an FDC appears to substantially improve 
adherence to a 3rd agent and the likelihood of achieving the accepted standard for 
adherence to HIV therapy of 95%. FDCs may improve overall adherence by increasing 
adherence to both the backbone and the 3rd component of the regimen.
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OBJECTIVES: This study is to assess the hepatitis C (HCV) burdens on health-related 
quality of life (HRQoL) and resource utilization in Europe. METHODS: Data from 
2006 to 2008 National Health and Wellness Survey (NHWS) in France, Germany, 
Italy, Spain, and UK were applied. Responders were representative adults. Those with 
self-reported hepatitis C were categorized as cases. Propensity-matched non-hepatitis 
survey responders were selected as controls based on country, gender, age, education, 
employment, and year of survey. HRQoL was collected from both SF-8/SF-12 and 
Work Productivity Activity Impairment (WPAI) standard instruments. The numbers 
of physician and emergency room (ER) visits were also collected. Conditional logistic 
regression was applied controlling for AIDS/HIV status, health status measured by the 
Charlson Index less hepatitis C, marital status, smoking status, alcohol consumption, 
and body mass index. RESULTS: The ﬁnal sample included 864 cases and 864 closely 
matched controls. Sixty-one percent were male with mean age of 49.8 years. HCV 
patients reported signiﬁcantly impaired HRQoL scores on both SF-8/SF-12 mental 
score and physical score (P  0.01). Work productivity was also reported lower for 
cases although not statistically signiﬁcant due to limited number of employed patients. 
In the six months prior to the survey, HCV patients, compared to controls, were 
 signiﬁcantly more likely to have an ER visit (OR  1.497, 95%CI: 1.092–2.051), sig-
niﬁcantly more likely to visit an internist (OR  2.297, 95%CI: 1.413–3.736), gastro-
enterologist (OR  1.997, 95%CI: 1.285–3.104), nephrologist (OR  3.149, 95%CI: 
1.142–8.682), or other medical specialist (OR  1.434, 95%CI: 1.054–2.050). Overall 
HCV patients reported 2.34 more medical visits than controls (95%CI: 1.1613–
3.5315) in the past six months. CONCLUSIONS: HCV infected patients in Europe 
reported signiﬁcantly lower HRQoL than non-HCV infected subjects, and were more 
likely to have ER and physician visits.
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OBJECTIVES: To evaluate the psychometric properties of the Functional Assessment         
of Human Immunodeﬁciency Virus Infection (FAHI) questionnaire, a 47-item disease-
speciﬁc instrument evaluating Health-Related Quality of Life (HRQL) in Human 
Immunodeﬁciency Virus (HIV) patients, and show its usefulness for the evaluation of 
new antiretroviral therapy. METHODS: Treatment-experienced HIV patients included    
in two independent clinical programmes completed the self-administered FAHI ques-
tionnaire at Baseline and after 24 weeks of treatment. The FAHI questionnaire 
includes ﬁve scales (physical well-being, emotional well-being, functional and global 
well-being, social well-being, cognitive functioning) and a total score, with higher 
scores indicating better HRQL. Psychometric properties of the FAHI questionnaire 
were assessed independently in both trial populations (N  565, 1096). A range of 
minimal important differences (MID) was provided using anchor-based and distribu-
tion-based methods. The link between HRQL and biological endpoints was explored 
by regression analysis. RESULTS: Internal consistency reliability was good, with      
Cronbach’s alphas ranging from 0.72 to 0.94. Most items met both convergent and 
discriminant validity criteria, demonstrating good construct validity of the scores. 
Clinical validity was demonstrated by better FAHI scores, indicating better HRQL for 
patients in earlier HIV stages. Changes in scores were signiﬁcantly linked to the change 
in EQ-5D score, demonstrating their responsiveness. MID ranged from 3.2 to 14 for 
the FAHI Total score. Regression analyses between the FAHI Total score and CD4 
cell count and viral load showed a poor relationships between HRQL and biological 
parameters (r-square 3%). CONCLUSIONS: The FAHI questionnaire demonstrated    
robust psychometric properties in two independent clinical trial populations. The 
assessment of HRQL enabled the detection of changes in patients’ health status not 
revealed by traditional clinical parameters of efﬁcacy.
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OBJECTIVES: To develop and validate a questionnaire for assessing patient satisfac-
tion with pharmaceutical care received in Nigerian HIV clinics. METHODS: Ques-
tionnaire’s items were selected from similar published studies and designed as 5-point 
Likert response scale. Face and content validity, feasibility, factorial validity, reliabil-
ity, discriminant and convergent validity were evaluated. The instrument’s feasiblity 
was assessed in a secondary health care facility (St. Charles Borromeo Hospital 
Onitsha) and validated in a tertiary health care facility (University of Nigeria Teaching 
Hospital Enugu). Factor analysis used principal components and varimax rotation. 
Reliability was established using internal consistency with Cronbach’s alpha. Conver-
gent and discriminant validity were determined using Spearman’s rho correlation. 
RESULTS: A self-administered questionnaire with 16 items, 5-point Likert response 
scale and demographic questions was designed. Questionnaire evaluates cumulative 
experience of patients with comprehensive pharmaceutical care practice in pharmacies 
of HIV clinics. Seventy questionnaires were collected for pilot test while four hundred 
questionnaires were retrieved for the validity test. Factor analysis resulted in four 
factors: relationship, patient counseling, drug information and patient care, with a 
cumulative variance of 56.7%. Cronbach’s alpha for the whole questionnaire was 
0.85, and 0.81, 0.66, 0.67 and 0.72 for the 4 factors, respectively. Four items used 
for convergent and discriminant validity showed convergence between the related 
items and variance between the unrelated items. CONCLUSIONS: The questionnaire 
developed can be a reliable and valid instrument to assess patient satisfaction with 
pharmaceutical care in HIV clinics in Nigeria. Further research is needed to re-validate 
the instrument.
PIN70
PERCEPTION AND ACCEPTANCE OF INTRADERMAL INFLUENZA 
VACCINE MEASURED BY THE VACCINEE’S PERCEPTION OF INJECTION 
(VAPI©) QUESTIONNAIRE
Meunier J1, Reygrobellet C2, Weber F2, Nguyen VH3, Viala-Danten M4
1Mapi Values, Lyon, France, 2Sanoﬁ pasteur, Lyon, France, 3Sanoﬁ Pasteur, Lyon, France, 
4Mapi Values France, Lyon, France
OBJECTIVES: During the clinical development of a new intradermal inﬂuenza vaccine          
given using a microinjection system, in parallel with the conventional evaluation of 
vaccine reactogenicity, perception and acceptability of injection site reactions (ISR) 
were assessed using the VAPI© self-administered questionnaire developed and vali-
dated as previously described (Chevat et al, Health and Quality of Life Outcomes 
2009, 7:21). METHODS: The questionnaire was speciﬁcally developed and validated       
according to recommended methods to assess vaccinees’ perception of ISR. It was 
completed 21 days after intradermal or intramuscular vaccination by elderly and non-
elderly participants in two European, randomised, controlled, phase 3 trials. It was 
divided into 4 dimensions: “bother” (6 items), “arm movement” (4 items), “sleep” 
(4 items), “acceptability” (2 items), and 5 individual items: anxiety before and after 
vaccination, bother by pain during injection, satisfaction with injection system and 
willingness to be vaccinated again. Scores range from 1 to 5 (1 being the most favour-
able opinion). RESULTS: Of the 5,562 trial participants, 5,305 returned the question-        
naire with at least one item completed. Mean scores were low (a1.68 in non-elderly, 
a1.48 in elderly) in both vaccine groups, indicating that ISR did not bother partici-
pants or affect their sleep or arm movement (at least 75% were not at all affected). 
In the ID group, among those who answered the questions, 96% of non-elderly and 
97% of elderly participants considered ISR caused by vaccination as being “totally” 
or “very” acceptable; 96% of both non-elderly and elderly participants were “very 
satisﬁed” or “satisﬁed” with the injection system; and 85% of non-elderly and 89% 
of elderly participants wanted to be vaccinated again. CONCLUSIONS: ISR were  
well accepted by participants, and were generally not a cause for concern. The level 
of satisfaction of the participants with the injection system was high, as was the 
willingness to be vaccinated again.
